The past decade has seen tremendous progress in the delivery of treatment of HIV-infected individuals worldwide. Better antiretroviral therapy (ART), improved laboratory monitoring, and evidence of ART as prevention have led to the possibility of beginning to reverse the AIDS pandemic. At the same time, limited resources worldwide have tempered the ability of the international community to optimally utilize these proven interventions. In 2004 and in 2008, NIAID awarded our research group funding to develop and expand the Cost-Effectiveness of Preventing AIDS Complications International (CEPAC-I) Model, a computer simulation of the natural history, clinical management, outcomes, and cost-effectiveness of HIV treatment in 3 resource- limited settings: South Africa, C?te d'lvoire, and India. In the last 5-year cycle of the project, this collaboration produced more than 105 original papers in peer-reviewed journals. In this continuation, we propose to further expand the CEPAC-I Model to reflect important developments in HIV/AIDS, and to address several of the most pressing questions in HIV care. We have three specific aims:
Specific Aim 1 : To examine the optimal packages of HIV care - ART initiation, monitoring strategies including use of point-of-care tests, and regimen sequencing - given varying resource constraints in South Africa, C?te d'Ivoire, India, and Brazil. We will create a new web-based 'metamodel'structure to allow clinical policy makers in other countries to access the capabilities of the CEPAC-I Model.
Specific Aim 2 : To define the benchmarks of clinical efficacy and cost by which new technologies - including long-acting ART and strategies for HIV eradication - may become viable and cost-effective options. We will perform analyses to establish performance requirements for new HIV treatments in resource-limited settings to be cost-effective. Novel modeling methods will incorporate patient heterogeneity as well as expanded probabilistic sensitivity analysis.
Specific Aim 3 : To project clinical outcomes, cost, and cost-effectiveness of detection and treatment for major co-morbidities in people with HIV, including hepatitis B and C viruses, TB, and hypertension. We will assess the cost-effectiveness of merging HIV care with screening and treatment for other common diseases in people with HIV. With new approaches to costing and budget impact analysis, we will assess the affordability of broadening HIV treatment programs. The assembled internationally-recognized, multidisciplinary research team has a lengthy record of disseminating findings to inform HIV care and guidelines, both in the US and internationally. To expand the project scope, we have added investigators from Brazil, the most HIV-affected country in Latin America. By leveraging the team's progress over the past 9 years and accomplishing the aims above, the proposed studies will answer many critical HIV clinical and policy questions facing the global HIV community.
With extraordinary progress in delivering HIV treatment and care in resource-limited settings over the past decade, there is now unprecedented opportunity to further improve outcomes and reverse the trajectory of the HIV/AIDS pandemic. The CEPAC-International Model provides a detailed and sophisticated modeling environment which is uniquely able to address the role of clinical interventions in HIV in the context of their broader public health implications and economic impact. This methodology allows investigation of problems from multiple directions in four countries representing different regions of the world and provides clear insight into proven as well as evolving approaches to HIV care.
|Ouattara, Eric N; Robine, Marion; EholiÃ©, Serge P et al. (2016) Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clin Infect Dis 62:1454-62|
|Francke, Jordan A; Penazzato, Martina; Hou, Taige et al. (2016) Clinical Impact and Cost-effectiveness of Diagnosing HIV Infection During Early Infancy in South Africa: Test Timing and Frequency. J Infect Dis 214:1319-1328|
|Walensky, Rochelle P; Jacobsen, Margo M; Bekker, Linda-Gail et al. (2016) Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis 213:1523-31|
|Blaser, Nello; Zahnd, Cindy; Hermans, Sabine et al. (2016) Tuberculosis in Cape Town: An age-structured transmission model. Epidemics 14:54-61|
|Luz, Paula M; Grinsztejn, Beatriz; Veloso, Valdilea G et al. (2016) Authors' Reply: Is Genotype Testing Really Cost-Effective for Primary Resistance in Brazil? J Acquir Immune Defic Syndr 71:e56|
|Ahonkhai, Aimalohi A; Banigbe, Bolanle; Adeola, Juliet et al. (2016) Age Matters: Increased Risk of Inconsistent HIV Care and Viremia Among Adolescents and Young Adults on Antiretroviral Therapy in Nigeria. J Adolesc Health 59:298-304|
|Walensky, Rochelle P; Borre, Ethan D; Bekker, Linda-Gail et al. (2016) The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. Ann Intern Med 165:325-33|
|Luz, Paula M; Girouard, Michael P; Grinsztejn, Beatriz et al. (2016) Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. J Int AIDS Soc 19:20623|
|Bassett, Ingrid V; Coleman, Sharon M; Giddy, Janet et al. (2016) Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa. J Acquir Immune Defic Syndr 73:154-60|
|O'Laughlin, Kelli N; Rabideau, Dustin J; Kasozi, Julius et al. (2016) Predictors of HIV infection: a prospective HIV screening study in a Ugandan refugee settlement. BMC Infect Dis 16:695|
Showing the most recent 10 out of 189 publications